James T Dalton
Dalton, J. T.
Dalton, James Tilmon, 1962-
VIAF ID: 88536605 (Personal)
Permalink: http://viaf.org/viaf/88536605
Preferred Forms
- 100 1 _ ‡a Dalton, J. T.
- 100 1 _ ‡a Dalton, James Tilmon, ‡d 1962-
- 100 0 _ ‡a James T Dalton
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia | |
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition | |
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma | |
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma | |
The genomic landscape of childhood and adolescent melanoma. | |
GTx-822, an ER{beta}-selective agonist, protects retinal pigment epithelium (ARPE-19) from oxidative stress by activating MAPK and PI3-K pathways. | |
Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes | |
Inhibitors of tubulin assembly identified through screening a compound library | |
Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase | |
The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing | |
LG-10GENETIC ALTERATIONS IN UNCOMMON LOW-GRADE NEUROEPITHELIAL TUMORS: BRAF, FGFR1, AND MYB MUTATIONS OCCUR AT HIGH FREQUENCY AND ALIGN WITH MORPHOLOGY. | |
Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls | |
Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature | |
MicroRNAs are mediators of androgen action in prostate and muscle | |
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas | |
Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134. | |
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies | |
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas | |
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. | |
A novel liposomal formulation of flavopiridol | |
A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies | |
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis | |
Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? | |
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer | |
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators | |
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis | |
Pharmacokinetic and pharmacodynamic implications of drug absorption from urinary bladder, 1990 | |
Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. | |
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. | |
Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study | |
Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue | |
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. | |
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia | |
Polar spongioblastoma of the spinal cord: a case report | |
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients | |
Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150 | |
Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer | |
Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. | |
Recombinant expression and purification of human androgen receptor in a baculovirus system. | |
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. | |
Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen | |
Role of nuclear receptors in lipid dysfunction and obesity-related diseases. | |
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. | |
Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling | |
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer | |
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease | |
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. | |
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth | |
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor | |
Structural basis for antagonism and resistance of bicalutamide in prostate cancer | |
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids | |
Structure and evolution of double minutes in diagnosis and relapse brain tumors | |
Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. | |
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials) | |
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. | |
Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer | |
Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides | |
Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. | |
Synthesis of oxazolidinedione derived bicalutamide analogs. | |
TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms | |
Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery | |
Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation | |
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia | |
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. | |
Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets | |
Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus | |
YAP1-fusions in pediatric NF2-wildtype meningioma | |
β-LGND2, an ERβ selective agonist, inhibits pathologic retinal neovascularization |